Digoxin and Mortality in Patients With Atrial Fibrillation

Journal of the American College of Cardiology

Volumn 71, Issue 10, 2018, Pages 1063-1074

  Lopes, Renato D ^a   Rordorf, Roberto ^b   De Ferrari, Gaetano M ^b   Leonardi, Sergio ^b   Thomas, Laine ^a   Wojdyla, Daniel M ^a   Ridefelt, Peter ^c   Lawrence, John H ^d   De Caterina, Raffaele ^e   Vinereanu, Dragos ^f   Hanna, Michael ^e   Flaker, Greg ^g   Al Khatib, Sana M ^a   Hohnloser, Stefan H ^h   Alexander, John H ^a   Granger, Christopher B ^a   Wallentin, Lars ^c,i  

^a DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF PAVIA   (Italy)

^c UPPSALA UNIVERSITY   (Sweden)

^d BRISTOL MYERS SQUIBB   (United States)

^e UNIVERSITY OF CHIETI   (Italy)

^f CAROL DAVILA UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

^g UNIVERSITY OF MISSOURI   (United States)

^h GOETHE UNIVERSITY   (Germany)

ⁱ UPPSALA CLINICAL RESEARCH CENTER   (Sweden)

Author keywords

atrial fibrillation; digoxin; heart failure; mortality

Indexed keywords

DIGOXIN;

ADULT; AGED; ARTICLE; ATRIAL FIBRILLATION; CAUSE OF DEATH; CONTROLLED STUDY; FEMALE; FOLLOW UP; HEART FAILURE; HUMAN; INFORMED CONSENT; MAJOR CLINICAL STUDY; MALE; MORTALITY; POPULATION RESEARCH; POST HOC ANALYSIS; PRACTICE GUIDELINE; PREVALENCE; PRIORITY JOURNAL; PROPENSITY SCORE; RISK FACTOR; SUDDEN DEATH;

EID: 85042306799     PISSN: 07351097     EISSN: 15583597     Source Type: Journal    
DOI: 10.1016/j.jacc.2017.12.060     Document Type: Article

References (42)

1. January, C.T., Wann, L.S., Alpert, J.S., et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation. J Am Coll Cardiol 64 (2014), 2246–2280.
2. Kirchhof, P., Benussi, S., Kotecha, D., et al. 2016 ESC guidelines for the management of atrial fibrillation. Eur Heart J 37 (2016), 2893–2962.
3. Digitalis Investigation Group. The effect of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med 336 (1997), 525–533.
4. Allen, L.A., Fonarow, G.C., Simon, D.N., et al. Digoxin use and subsequent outcomes among patients in a contemporary atrial fibrillation cohort. J Am Coll Cardiol 65 (2015), 2691–2698.
5. Washam, J.B., Stevens, S.R., Lokhnygina, Y., et al. Digoxin use in patients with atrial fibrillation and adverse cardiovascular outcomes: a retrospective analysis of ROCKET AF. Lancet 385 (2015), 2363–2370.
6. Gjesdal, K., Feyzi, J., Olsson, S.B., Digitalis: a dangerous drug in atrial fibrillation? An analysis of the SPORTIF III and V data. Heart 94 (2008), 191–196.
7. Whitbeck, M.G., Charnigo, R.J., Khairy, P., et al. Increased mortality among patients taking digoxin—analysis from the AFFIRM study. Eur Heart J 34 (2013), 1481–1488.
8. Hallberg, P., Lindbäck, J., Lindahl, B., Stenestrand, U., Melhus, H., Digoxin and mortality in atrial fibrillation: a prospective cohort study. Eur J Clin Pharmacol 63 (2007), 959–971.
9. Turakhia, M.P., Santangeli, P., Winkelmayer, W.C., et al. Increased mortality associated with digoxin in contemporary patients with atrial fibrillation: findings from the TREAT-AF study. J Am Coll Cardiol 64 (2014), 660–668.
10. Chao, T.F., Liu, C.J., Tuan, T.C., et al. Rate-control treatment and mortality in atrial fibrillation. Circulation 132 (2015), 1604–1612.
11. Freeman, J.V., Reynolds, K., Fang, M., et al. Digoxin and risk of death in adults with atrial fibrillation: the ATRIA-CVRN study. Circ Arrhythm Electrophysiol 8 (2015), 49–58.
12. Pastori, D., Farcomeni, A., Bucci, T., et al. Digoxin treatment is associated with increased total and cardiovascular mortality in anticoagulated patients with atrial fibrillation. Int J Cardiol 180 (2015), 1–5.
13. Vamos, M., Erath, J.W., Hohnloser, S.H., Digoxin-associated mortality: a systematic review and meta-analysis of the literature. Eur Heart J 36 (2015), 1831–1838.
14. Shah, M., Avgil Tsadok, M., et al. Relation of digoxin use in atrial fibrillation and the risk of all-cause mortality in patients ≥65 years of age with versus without heart failure. Am J Cardiol 114 (2014), 401–406.
15. Eisen, A., Ruff, C.T., Braunwald, E., et al. Digoxin use and subsequent clinical outcomes in patients with atrial fibrillation with or without heart failure in the ENGAGE AF-TIMI 48 Trial. J Am Heart Assoc, 6, 2017 pii:e006035.
16. Adedinsewo, D., Xu, J., Agasthi, P., Oderinde, A., et al. Effect of digoxin use among Medicaid enrollees with atrial fibrillation. Circ Arrhythm Electrophysiol, 10, 2017, e004573.
17. Friberg, L., Hammar, N., Rosenqvist, M., Digoxin in atrial fibrillation: report from the Stockholm Cohort study of Atrial Fibrillation. Heart 96 (2010), 275–280.
18. Gheorghiade, M., Fonarow, G.C., van Veldhuisen, D.J., et al. Lack of evidence of increased mortality among patients with atrial fibrillation taking digoxin: findings from post hoc propensity-matched analysis of the AFFIRM trial. Eur Heart J 34 (2013), 1489–1497.
19. Mulder, B.A., Van Veldhuisen, D.J., Crijns, H.J., et al. Digoxin in patients with permanent atrial fibrillation: data from the RACE II study. Heart Rhythm 11 (2014), 1543–1550.
20. Master, J., Schweitzer, P., Is there a role for digoxin in atrial fibrillation without heart failure?. Cardiol J 16 (2009), 483–486.
21. Qureshi, W., O'Neal, W.T., Soliman, E.Z., Al-Mallah, M.H., Systematic review and meta-analysis of mortality and digoxin use in atrial fibrillation. Cardiol J 23 (2016), 333–343.
22. Chen, Y., Cai, X., Huang, W., Wu, Y., Huang, Y., Hu, Y., Increased all-cause mortality associated with digoxin therapy in patients with atrial fibrillation: an updated meta-analysis. Medicine (Baltimore), 94, 2015, e2409.
23. Wang, Z.Q., Zhang, R., Chen, M.T., et al. Digoxin is associated with increased all-cause mortality in patients with atrial fibrillation regardless of concomitant heart failure: a meta-analysis. J Cardiovasc Pharmacol 66 (2015), 270–275.
24. Bavishi, C., Khan, A.R., Ather, S., Digoxin in patients with atrial fibrillation and heart failure: a meta-analysis. Int J Cardiol 188 (2015), 99–101.
25. Ouyang, A.J., Lv, Y.N., Zhong, H.L., et al. Meta-analysis of digoxin use and risk of mortality in patients with atrial fibrillation. Am J Cardiol 115 (2015), 901–906.
26. Ziff, O.J., Lane, D.A., Samra, M., et al. Safety and efficacy of digoxin: a systematic review and meta-analysis of observational and controlled trial data. BMJ, 351, 2015, h4451.
27. Bavendiek, U., Aguirre Davila, L., Koch, A., Bauersachs, J., Assumption versus evidence: the case of digoxin in atrial fibrillation and heart failure. Eur Heart J 38 (2017), 2095–2099.
28. Ziff, O.J., Kotecha, D., Digoxin: the good and the bad. Trends Cardiovasc Med 26 (2016), 585–595.
29. Rathore, S.S., Curtis, J.P., Wang, Y., Bristow, M.R., Krumholz, H.M., Association of serum digoxin concentration and outcomes in patients with heart failure. JAMA 289 (2003), 871–878.
30. Lopes, R.D., Alexander, J.H., Al-Khatib, S.M., et al. Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial: design and rationale. Am Heart J 159 (2010), 331–339.
31. Granger, C.B., Alexander, J.H., McMurray, J.J., et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 365 (2011), 981–992.
32. Wallentin, L., Hijazi, Z., Andersson, U., et al. Growth differentiation factor 15, a marker of oxidative stress and inflammation, for risk assessment in patients with atrial fibrillation: insights from ARISTOTLE. Circulation 130 (2014), 1847–1858.
33. Hijazi, Z., Wallentin, L., Siegbahn, A., et al. N-terminal pro-B-type natriuretic peptide for risk assessment in patients with atrial fibrillation: insights from ARISTOTLE. J Am Coll Cardiol 61 (2013), 2274–2284.
34. Hijazi, Z., Wallentin, L., Siegbahn, A., et al. High-sensitivity troponin T and risk stratification in patients with atrial fibrillation during treatment with apixaban or warfarin. J Am Coll Cardiol 63 (2014), 52–61.
35. Hijazi, Z., Siegbahn, A., Andersson, U., et al. High-sensitivity troponin I for risk assessment in patients with atrial fibrillation: insights from ARISTOTLE. Circulation 129 (2014), 625–634.
36. Li F, Morgan KL, Zaslavsky AM. Balancing covariates via propensity score weighting. J Am Stat Assoc 2017. In press.
37. Van Buuren, S., Multiple imputation of discrete and continuous data by fully conditional specification. Stat Methods Med Res 16 (2007), 219–242.
38. Li, Y.P., Propert, K.J., Rosenbaum, P.R., Balanced risk set matching. J Am Stat Assoc 96 (2001), 870–882.
39. Bo, L., Propensity score matching with time-dependent covariates. Biometrics 61 (2005), 721–728.
40. Goldberger, Z.D., Alexander, G.C., Digitalis use in contemporary clinical practice: refitting the foxglove. JAMA Intern Med 174 (2014), 151–154.
41. Adams, K.F. Jr., Butler, J., Patterson, J.H., et al. Dose response characterization of the association of serum digoxin concentration with mortality outcomes in the Digitalis Investigation Group trial. Eur J Heart Fail 18 (2016), 1072–1081.
42. Hohnloser, S.H., Halperin, J.L., Camm, A.J., Gao, P., Radzik, D., Connolly, S.J., Interaction between digoxin and dronedarone in the PALLAS trial. Circ Arrhythm Electrophysiol 7 (2014), 1019–1025.